Agonist News and Research

RSS

Phase 2 trial reveals Lixisenatide may reduce motor disability in Parkinson’s patients

A trial of lixisenatide to assess its effects in early Parkinson’s disease.

18 Apr 2024

Opioid dependence in Scotland remains high but largely stable, study shows

Opioid dependence in Scotland remains high but largely stable, according to a new University of Bristol-led analysis published in Addiction today [18 April] and by Public Health Scotland.

17 Apr 2024

Popular diabetes drugs not linked to thyroid cancer risk, study finds

Study reveals crucial insights into the ocular effects of Zika virus infection during pregnancy

A groundbreaking study published in the journal iScience presents crucial insights into the ocular effects of Zika virus infection during pregnancy and offers promising avenues for therapeutic intervention.

28 Mar 2024

Weight loss drugs associated with increased risk of aspiration pneumonia following endoscopy

New research from Cedars-Sinai suggests people who are scheduled for certain medical procedures should stop taking popular weight loss drugs in the days or weeks prior to avoid complications.

27 Mar 2024

AI-based analysis uncovers two plant extracts with potential as GLP-1 agonist weight loss pills

Two plant compounds with potential as GLP-1 agonist weight loss pills have been identified in an AI (artificial intelligence)-based study, the European Congress on Obesity (ECO 2024) (Venice 12-15 May), will hear.

26 Mar 2024

A paramedic was skeptical about this Rx for stopping repeat opioid overdoses. Then he saw it help.

Fire Capt. Jesse Blaire steered his SUV through the mobile home park until he spotted the little beige house with white trim and radioed to let dispatchers know he'd arrived.

25 Mar 2024

Relugolix and radiation therapy may be a safe, effective combination for treating prostate cancer

A high impact study led by Daniel Spratt, M.D., Vincent K. Smith Chair in Radiation Oncology at University Hospitals Seidman Cancer Center demonstrates the safety and efficacy of a novel oral hormone therapy, relugolix, in conjunction with radiation therapy for treating men with localized and advanced prostate cancer.

13 Mar 2024

Study reveals key mechanism of PD-1 function

Insights into the workings of an immune cell surface receptor, called PD-1, reveal how treatments that restrict its action can potentially be strengthened to improve their anticancer effect, a new study shows.

9 Mar 2024

Diabetes drug dulaglutide may reduce symptoms of depression

The current study highlighted the antidepressant effects of dulaglutide using the CMS depression model. Notably, the potential metabolisms that underlie the antidepressant effect of dulaglutide have been elucidated in this study.

8 Mar 2024

Study reveals mechanisms behind antidepressant effects of diabetes drug

Research in animals has shown that the diabetes drug dulaglutide, which is a glucagon-like peptide-1 (GLP-1) receptor agonist may reduce symptoms of depression.

6 Mar 2024

Exercise, GLP-1 receptor agonist, or combined approach explored in year-long study

Researchers compare the extent of weight loss after one-year termination of active intervention with GLP-1 receptor agonist, exercise, or combination.

29 Feb 2024

Study: Potential biomarker in the blood predicts sudden cardiac deaths

The discovery of a biomarker readily measured in blood could be a significant step towards preventing sudden deaths.

28 Feb 2024

Novel insights into pathologies of diabetic cardiomyopathy, hippocampal neurotoxicity, and Alzheimer’s

DCM is the leading cause of heart failure in patients with chronic diabetes. However, the underlying mechanisms of DCM are poorly understood, and treatment options are limited.

26 Feb 2024

Yale School of Medicine secures $575,000 grant for Long COVID research

Yale School of Medicine and its Center for Infection & Immunity (CII) are receiving a $575,000 grant from PolyBio Research Foundation to fund Long COVID research.

23 Feb 2024

Delta opioid receptor agonist reduces anxiety-like behavior in mice

Anxiety-related disorders can have a profound impact on the mental health and quality of life of affected individuals.

22 Feb 2024

Intravenous DMT shows promise in reducing depression symptoms, study reveals

A study in Scientific Reports shows intravenous DMT can significantly reduce depression severity in healthy volunteers, highlighting its potential as a therapeutic psychedelic intervention for mental health disorders.

8 Feb 2024

AMG 133 (maridebart cafraglutide) weight loss drug shows promise in early trial

AMG 133, an engineered bispecific molecule, demonstrated significant weight loss with a favorable safety profile in a phase 1 clinical trial, offering a promising new treatment option for obesity.

7 Feb 2024

New weight loss drug may be an effective strategy for preventing or treating high blood pressure

The new weight loss medication tirzepatide significantly lowered the systolic blood pressure (the top number in a blood pressure reading) for nearly 500 adults with obesity who took the medication for about eight months, according to new research published today in Hypertension, an American Heart Association journal.

5 Feb 2024

Breakthrough obesity treatments on the horizon, rivaling surgery's success

New obesity pharmacotherapies, including GLP-1 receptor agonists and combinations of entero-pancreatic hormones, show promise in achieving significant weight loss, potentially rivaling bariatric surgery's effectiveness.

4 Feb 2024